Primary hyperparathyroidism

Zeynep Cetin*
Endocrinology and Metabolism Department, Sabuncuoglu Serefeddin Education and Research Hospital, Amasya University, Turkey

Abstract

Primary hyperparathyroidism (PHPT) is an endocrinological disease with parathormone (PTH) and calcium elevation. It is the most common form of hypercalcemia in the community. In this review, the definition, diagnosis, differential diagnosis and treatment of hyperparathyroidism are described.

Introduction

PHPT is characterized by increased PTH release from one or more parathyroid glands. It causes hypercalcemia. This hypercalcemia also leads to osteoporosis, bone fracture, urinary stone, kidney failure and adversely affects many systems. It is one of the most common endocrine diseases [1]. After 1970s, serum calcium entered the routine of measurement and the diagnosis of mild and/or symptomatic PHPT began to increase, not only symptomatic and severe PHPTs [2]. Nowadays, it presents in 3 ways:

1. Classic PHPT: condition with symptoms and signs specific to disease with high PTH and calcium [3].

2. Normocalcemic PHPT: Clinical form where total and ionized calcium levels are normal when PTH is high [3]. In order to make this sub-diagnosis, the level of vitamin D should be normal (> 20 ng/ml) and the other causes of secondary hyperparathyroidism (malabsorption, chronic kidney disease, hypercalciuria) should be excluded. Since vitamin D deficiency may mask hypercalcemia, hyperparathyroidism secondary to vitamin D deficiency should not be incorrectly called normocalcemic PHPT. After vitamin D replacement, the actual subtype of PHPT can be detected [2].

3. Asymptomatic PHPT: High PTH and calcium are not accompanied by clinical findings [3].

Pathophysiology

Increased PTH acts on bone, kidney and small intestine. PTH directly stimulates osteoblasts, they release osteoclast-stimulating factors such as interleukin–6, thereby osteoclast activity increases. Increased osteoclast activity suppresses bone formation, increases resorption, thereby leading to bone loss and hypercalcemia. PTH causes an increase in calcium reabsorption and phosphorus excretion with direct effect on the kidneys and induces active vitamin D (1,25 dihydroxyvitamin) production by increasing the activity of 1 alpha hydroxylase enzyme, active vitamin D leads to an increase in calcium absorption from the small intestine. As a result, there is an increase in the level of calcium in the blood [4,5].

Etiology

Primary hyperparathyroidism is the third most common endocrinological disease in the community after diabetes and thyroid diseases [6]. Its prevalence is about 1%. It is most commonly seen between the ages of 50–60. It is 3 times more common in women than in men, especially more common in postmenopausal women [7]. Since the 1970s, the prevalence of both PHPT and asymptomatic and mild PHPT has increased, with routine maintenance of serum calcium, widespread neck ultrasonography and osteoporosis screening. Asymptomatic PHPT rates of up to 80% are reported in some series. Especially in the USA and Europe, the diagnosis of mild/ asymptomatic PHPT is more common than the obvious PHPT [8].
PHPT is usually sporadic, about 90% of which are solitary adenoma. 5%–10% of PHPT is due to muligland disease (multiple adenomas or hyperplasia), 1-3 % is caused by parathyroid carcinoma [7,8].

Approximately 10% of PHPT patients have a hereditary mutation. These mutations are mostly related to multiple endocrine neoplasia (MEN) type 1 (menin gene mutation on 11q13), MEN 2A (RET gene mutation on 10q11.2), familial isolated primary hyperparathyroidism (menin, parafibromin, CASR, CDKN1A, CDKN2B or CDKN2C mutations), hyperparathyroidism-jaw tumor syndrome (parafibromin gene mutation on 1q31.2) [9]. Its incidence is 13–36 in 10000 patient years in women and 66 in men. It is about 4 times more common in women [8]. (In which patients genetic testing is required, the diagnosis section is mentioned below).

Clinical symptoms and signs

In symptomatic PHPT, symptoms / signs can develop in almost any system:

Urinary system: polyuria, polydipsia, nephrolithiasis, nephrocalcinosis. PTH leads to an increase in calcium reabsorption and phosphorus excretion in the kidneys. In PHPT, when the filter calcium load exceeds its absorption capacity, it leads to hypercalciuria, which starts the formation of stones and calcinosis.

Gastointestinal tract: nausea, vomiting, acute pancreatitis, peptic ulcer. Peptic ulcer is generally seen in syndromic patients, especially in MEN1 and MEN4 because the frequency of gastrin-related tumors has increased in these syndromes. Whether there is a causal relationship between PHPT and acute pancreatitis has not been established yet.

Musculoskeletal system: weakness, bone pain, osteopenia / osteoporosis, brown tumor (osteitis fibrosa cystica). Chronic PTH elevation, through receptor activator of nuclear factor-κB ligand (RANKL), particularly affects distal radius, leading to bone loss, osteoporosis and pathological fractures. Osteitis fibrosa cystica occurs in 6.1% of patients. Recently, it is a less common bone complication characterized by bone loss, fibrosis and bone cyst.

Cardiovascular system: hypertension, arrhythmia, left ventricular hyperplasia. These findings are more common with PTH and calcium elevation. In asymptomatic / mild disease, the opposite is the case.

Neuropsychiatric system: depression, anxiety, concentration defect, stupor, coma. These findings are more common in correlation with high calcium and PTH, and low vitamin D, but there was no improvement in all after successful treatment [4].

Diagnosis

Laboratory is very helpful in diagnosis. Serum calcium is normal / high, phosphorus is low / normal, PTH is close to normal upper limit / high, 25 hydrox(OH) vitamin D is low / normal (due to an increase in 25 (OH) vitamin D clearance under the influence of 1 alpha hydroxylation). There are mild hyperchloremic acidosis, increase in bone alkaline phosphatase and urinary calcium excretion (> 400 mg / day). Calcium / creatinine clearance rate is > 0.01. Depending on the severity of the disease, the glomerular filtration rate may decrease [10].

In classical PHPT, hypercalcemia, hypophosphatemia and PTH are above the upper normal limit and clinical symptoms / signs are detected. If calcium is high, PTH is not suppressed, it is in favor of PHPT. However, today there is an increase in the frequency of mild symptomatic / asymptomatic PHPT and normocalcemic PHPT. Normocalcemic PHPT is a diagnosis made to rule out secondary causes of hyperparathyroidism. It is considered as the early stage of the disease, and if the diagnosis is delayed, it turns into an obvious disease. Seconder causes of hyperparathyroidism are discussed in the differential diagnosis section [4].

Although it is not necessary for the diagnosis, performing localization studies in people who meet the surgical criteria will make surgery easier. Lesions on the neck can be detected by the neck USG, imaging methods such as 99mTc-methoxyisobutylisonitrile (MIBI) scintigraphy + single-photon emission computed tomography (CT), CT, magnetic resonance (MR), positron emission tomography (PET)/CT can be used in mediastinal or ectopic lesions [1].

Nephrolithiasis and / or nephrocalcinosis can be detected by direct radiography, urinary USG or other imaging methods. Bone mineral density is determined with dual X ray absorbiometry (DXA) or quantitative CT (QCT) [11].

Genetics: Genetic testing should be considered in the presence of young age (<45 years), multiligandular disease (> 2 gland), first degree relative hypercalcaemia, parathyroid carcinoma, atypical adenoma [8]. In atypical adenoma, there are at least two of these: tumor necrosis without missing invasion of the capsule, fibrous bands, trabecular growth, mitotic activity>1/10 HPF, tumor necrosis without definitive vascular invasion [12]. Genetic screening enables the application of adequate treatment, detection of other associated tumors, detection of index cases, avoiding unnecessary stress by identifying healthy family members [9].

Differential diagnosis

PHPT is a disease with normal / high calcium and normal / high PTH. In differential diagnosis, especially malignancy, familial hypocalciuric hypercalcemia (FHH), drugs and secondary HPT should be taken into consideration.

Hypercalcemia can be seen in many types of malignancy, especially solid organ tumors [13]. In malignancies, both the cancer’s self clinic and hypercalcemia clinic are faster and more severe, calcium is higher, especially PTH is too low or undetectable, these make it easy to distinguish from PHPT [14].

FHH is an autosomal dominant inherited disease. It is characterized by mild hypercalcemia and normal / mildly high PTH. Low urinary calcium helps distinguish it from PHPT.
It occurs due to inactivating mutation in calcium sensing receptors in parathyroid glands and kidneys. In these cases, the family story is positive. Genetic diagnosis is possible. Since it does not require treatment, differential diagnosis with PHPT is mandatory [15,16].

Lithium can cause downstream in calcium sensing receptors, similar to FHH, leading to a picture with hypercalcemia and hypocalciuria. With the discontinuation of the drug, the picture returns in most patients. Thiazide diuretics may decrease urinary calcium excretion and cause mild hypercalcemia. Calcium level returns to normal following discontinuation of the drug [17,18].

Secondary hyperparathyroidism is an increase in PTH secretion from parathyroid glands due to a decrease in extracellular calcium level. When PTH is high, serum calcium or ionized calcium is low or at the low normal limit. It is seen in cases of malabsorption, vitamin D deficiency (<20 ng/ml), bariatric surgery, kidney failure, loop diuretics, pseudohyperparathyroidism (genetic resistance to PTH, hypocalcemia, elevated PTH), hungry bone syndrome, antiresorptive agents (bisphosponat, denosumab) [4,19,20].

Treatment and follow up

In patients with a diagnosis of PHPT, the necessity for surgery should first be decided for treatment. Surgical treatment is indicated if there is nephrolithiasis, low creatinine clearance (GFR) unexplained for other reasons, presence of hyperparathyroidic bone disease, signs of hypercalcemia and/or life-threatening attacks of hypercalcemia. Unless asymptomatic PHPT was treated, an increased risk of vertebral fracture and kidney stone was found. Thus asymptomatic patients should be screened for these complications (4). In asymptomatic PHPT, surgery is indicated if one of the following is present: age <50 years, serum calcium with 1 mg/dl above the upper limit, GFR is lower than 60 ml/minutes, vertebra, hip or distal radius T score <-2.5 in DXA, vertebral fracture, urinary calcium excretion> 400 mg / day, nephrolithiasis or nephrocalcinosis [21,22].

The standard surgical procedure is bilateral cervical exploration with a 95–98% cure rate. This method should be preferred in PHPTH associated with genetic syndrome or where the lesion location cannot be detected or multigland involvement. Minimally invasive parathyroidectomy can be selected in single adenoma operation if intraoperative PTH can be performed and the surgical team is experienced. In these cases, endoscopic methods may also be an option [22,23].

With experienced surgeon, complications are few. These are laryngeal nerve damage (<1%), symptomatic moderate postoperative hypocalcemia (15%–30%), hungry bone syndrome (HBS), wound complications, cervical hematoma. Mortality rate is low but it can be seen up to 10% in the elderly [22,24].

HBS is a complication after parathyroidectomy with a frequency of 13%. Impaired balance between bone resorption–formation after surgery causes it. Hypocalcemia may be accompanied by elevated PTH. Risk factors include vitamin D deficiency, alkaline phosphatase elevation, large parathyroid lesion, parathyroid–matched thyroid surgery, prolonged surgery, advanced age. Some guidelines and studies suggest preoperative vitamin D replacement and the use of bisphosphonates to reduce HBS risk. These agents reduce bone demineralization [25,26].

Medical treatment indications in PHPT are: > 50 years of age, the patient is minimally symptomatic or asymptomatic, calcium is <1.0 mg / dl higher than the normal upper limit, has no surgical indication or the patient does not want surgery or the patient is not suitable for surgery. In these situations, patients are followed up by medical monitoring [11,22].

There is no need for calcium restriction in the diet. Abundant daily hydration is recommended. If vitamin D is low, it is recommended to be replaced. The risk of hypercalcemia is low. It provides a slight drop in PTH [27].

Antiresorptive agents (estrogen receptor–targeted drugs, bisphosphonates) can be used in the presence of osteopenia / osteoporosis, these drugs provide a slight drop in calcium. Treatment of bone loss caused by the disease is also provided [28,29].

Sinekalset, which is a calcimimetic agent, normalizes 80%–90% in serum calcium and provides an increase in phosphorus. Urinary calcium is reduced. It does not affect bone mineral density [27].

Patients who do not receive surgical or medical treatment should be followed up periodically, and should be applied without delay when treatment indication develops. Biochemical tests (serum calcium, creatinine, GFR) of these patients are recommended to be performed annually, BMD follow–up is performed once in 1 or 2 years [30–35].

References

1. Wojtczak B, Syrycka J, Kaliszewski K, Rudnicki J, Bolanowski M, et al. (2020) Surgical implications of recent modalities for parathyroid imaging. Gland Surg 9: S58-S59. Link: https://bit.ly/3czfqV4
2. Heath H, Hodgson SF, Kennedy MA (1980) Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302: 189-193. Link: https://bit.ly/2U9ykvy
3. Goldfarb M, Singer FR (2020) Recent advances in the understanding and management of primary hyperparathyroidism. Link: https://bit.ly/3gVtxHG
4. Bilezikian JP, Cusano NE, Khan AA, Liu JM, Marcocci C, et al. (2017) Primary hyperparathyroidism. Nat Rev Dis Primers 2: 16033.
5. Khan A, Bilezikian J (2000) Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ 163: 184-187. Link: https://bit.ly/30870Bu
6. Marcocci C, Cetani F (2011) Clinical practice. Primary hyperparathyroidism. N Engl J Med 365: 2389-2397. Link: https://bit.ly/2AF9PPM
7. Madkhali T, Alhefdhi A, Chen H, Ellenbein D (2016) Primary hyperparathyroidism. Ulus Cerrahi Derg 32: 58-66. Link: https://bit.ly/3dpzn6e
8. Silverberg SJ, Larke BL, Peacock M, Bandeira F, Boutroy S, et al. (2014) Current
issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99: 3580-3594. Link: https://bit.ly/2Mz5y2a

9. Eastell R, Brandi ML, Costa AG, D'Amour P, Shoback DM, et al. (2014) Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99: 3570-3579. Link: https://bit.ly/2Y3P33a

10. Syed H, Khan A (2017) Primary hyperparathyroidism: diagnosis and management in 2017. Polish Archives Of Internal Medicine 127: 438-441. Link: https://bit.ly/2XKyjB5

11. Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JEM, et al. (2017) Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int 28: 1-19. Link: https://bit.ly/2Msmg4p

12. Ramaswamy AS, Vijitha T, Ramaswamy S, Mahalingashetti PB (2017) Atypical parathyroid adenoma. Indian J Pathol Microbiol 60: 99-101.

13. Gastanaga WM, Schwartzberg LS, Jain RK, Pirolli M, Quach D, et al. (2016) Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302: 189-193. Link: https://bit.ly/3gZnLoO

14. Marx SJ (2018) Familial Hypocalciuric Hypercalcaemia as an Atypical Form of Primary Hyperparathyroidism. J Bone Miner Res 33: 27-31. Link: https://bit.ly/370GhpC

15. Tosur M, Lopez ME, Paul DL (2019) Primary hyperparathyroidism versus familial hypocalciuric hypercalcaemia: a challenging diagnostic evaluation in an adolescent female. Ann Pediatr Endocrinol Metab 24: 195-198. Link: https://bit.ly/2z3G2Qs

16. Bollerslev J, Bandeira L, Khan AA, Hanley DA, Shoback DM, et al. (2014) Hyperparathyroidism. Lancet 384: 342-355. Link: https://bit.ly/3eOiNJx

17. Marcocci C, Bollerslev J, Khan AA, Shoback DM (2014) Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99: 3561-3569. Link: https://bit.ly/3f3MtIj

18. Konala VM (2019) Lithium-induced Hyperparathyroidism. Ulus Cerrahi Derg 32: 58-66. Link: https://bit.ly/3dMeTFX

19. Chandran M, Wong J (2019) Secondary and Tertiary Hyperparathyroidism in Chronic Kidney Disease: An Endocrine and Renal Perspective. Indian J Endocrinol Metab 23: 391-399. Link: https://bit.ly/3gTQiaU

20. Coccia PA, Zaffo S, D'Amico G, Caino S, Cacioppo M, et al. (2017) The medical and surgical treatment in secondary and tertiary hyperparathyroidism. Review. Clin Ter 168: e158-e167. Link: https://bit.ly/376axA

21. Walker MD, Silverberg SJ (2018) Primary hyperparathyroidism 14: 115–125.

22. Udelsman R, Åkerström G, Biagini C, Duh QY, Miccoli P, et al. (2014) The management of Hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99: 3595–3606. Link: https://bit.ly/2MuLEl

23. Bilezikian JP, Brandi ML, Howard D, O'Connor P (2009) Primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99: 3580-3594. Link: https://bit.ly/2Xzhf08

24. Haddad R, Lappe J, Rexrode JM, Silverberg SJ, Udelsman R, et al. (2014) The management of Hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99: 3580-3594. Link: https://bit.ly/2Xwvqmy

25. Florakis D, Karakozis S, Balafouta ST, Makras P (2019) Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma. J Musculoskelet Neuronal Interact 19: 379-384. Link: https://bit.ly/3cyufU

26. Marcocci C, Bollerslev J, Khan AA, Shoback DM (2014) Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 99: 3607-3618. Link: https://bit.ly/2XxM08

27. Zanchetta JR, Bogado CE (2001) Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism. J Bone Miner Res 16: 705-713. Link: https://bit.ly/30bZ7qf

28. Khan AA, Bilezikian JP, Kung A, Nirmala S, Standish T, et al. (2009) Alendronate therapy in men with primary hyperparathyroidism Endocr Pract 15: 705-706. Link: https://bit.ly/374e3ok

29. Khan AA, Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, et al. (2014) Management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 99: 3561-3569. Link: https://bit.ly/3f3MtIj

30. Heath H, Hodgson SF, Kennedy MA (1980) Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 302: 189-193. Link: https://bit.ly/3gZnLoO

31. Madkhali T, Alhefdhi A, Chen H, Elfenbein D (2016) Primary hyperparathyroidism. Ulus Cerrahi Derg 32: 58-66. Link: https://bit.ly/3dMeTFX

32. Bilezikian JP, Brandi ML, Howard D, O'Connor P (2009) Primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab 99: 3580-3594. Link: https://bit.ly/3eOiNJx

33. Jakubauskas M, Beša V, Strupas K (2018) Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism. Acta Med Litu 25: 45–51. Link: https://bit.ly/2BB80Eb

34. Jakubauskas M, Beša V, Strupas K (2018) Risk factors of developing the hungry bone syndrome after parathyroidectomy for primary hyperparathyroidism. Acta Med Litu 25: 45–51. Link: https://bit.ly/2BB80Eb

35. Florakis D, Karakozis S, Balafouta ST, Makras P (2019) Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma. J Musculoskelet Neuronal Interact 19: 379-384. Link: https://bit.ly/3cyufU

36. Florakis D, Karakozis S, Balafouta ST, Makras P (2019) Lessons learned from the management of Hungry Bone Syndrome following the removal of an Atypical Parathyroid Adenoma. J Musculoskelet Neuronal Interact 19: 379-384. Link: https://bit.ly/3cyufU

Discover a bigger Impact and Visibility of your article with Peertechz Publications

Highlights
- Signatory publisher of ORCID
- Signatory Publisher of DORA (San Francisco Declaration on Research Assessment)
- Articles archived in world's renowned service providers such as Portico, CNKI, AGRIS, TDMNet, Base (Bielefeld University Library), CrossRef, Suiltin, J-Stage etc.
- Journals indexed in ICMJE, SHERPA/ROMEO, Google Scholar etc.
- OA-PMH (Open Archives Initiative Protocol for Metadata Harvesting)
- Dedicated Editorial Board for every journal
- Accurate and rapid peer review process
- Increased citations of published articles through promotions
- Reduced timeline for article publication

Submit your articles and experience a new surge in publication services [https://www.peertechz.com/submission]

Copyright: © 2020 Cetin Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Cetin Z (2020) Primary hyperparathyroidism. Int J Clin Endocrinol Metab 6(1): 010-014. DOI: https://dx.doi.org/10.17352/ijcem.000045